Answers are grounded in this paper and cite their sources.
Graves’ disease (GD) impairs quality of life (QoL), and the effects of different treatments, including antithyroid drugs (ATD), radioiodine (RAI), and surgery, on QoL remain unclear. This study aimed to assess and compare QoL outcomes following these therapies. We conducted a PRISMA-based systematic review and meta-analysis, searching PubMed, Embase, Scopus, and Web of Science to July 30, 2025, for studies assessing QoL after GD treatment using generic SF-36 or thyroid-specific ThyPRO questionnaires. Mean scores were pooled using random-effects models. Sixteen studies were included. Among SF-36 domains, physical functioning had the highest scores for ATD (66.24 [43.97–88.50]) and RAI (84.02 [78.53–89.52]), while social functioning was highest after surgery (72.32 [55.62–89.01]). Vitality was among the lowest-scoring domains for ATD (55.90 [44.63–67.16]), RAI (59.35 [50.35–68.34]), and surgery (55.41 [47.10–63.71]), while bodily pain was lowest for surgery (51.11 [22.70–79.51]). In ThyPRO, tiredness was the worst-scoring domain for all treatments (ATD 40.04 [31.31–48.78]; surgery 32.50 [21.05–43.95]; RAI 41.90 [39.49–44.31]). The most favorable outcomes were observed for goiter symptoms after surgery (7.08 [0.42–13.74]) and RAI (12.03 [5.94–18.12]), and for sex life after ATD (11.59 [6.49–16.69]). Surgery showed significantly better QoL scores than RAI for depression and emotional susceptibility, while ATD was significantly better than RAI for sex life. All treatments were associated with improvements in QoL, with differences across specific domains. These findings may help clinicians and patients understand treatment-related QoL outcomes and support informed treatment decisions.
No takes yet. Share an insight, caveat, or question.
Mossavarali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: